The generic drug, montelukast should be offered to people ahead of combination inhalers such as GlaxoSmithKline's Seretide, in a bid to save the NHS millions of pounds, according to draft guidance ...
Introduction: The incidence of asthma exacerbations in patients receiving salmeterol/fluticasone propionate (Seretide™ or Advair ®) is low. However, when asthma control deteriorates, clinicians may ...
New data reveal that Ultibro (glycopyrronium bromide/ indacaterol) was superior to Seretide (salmeterol/fluticasone) in reducing flare ups in patients with moderate ...
Seretide/Advair is GSK’s best-selling drug, and the line was extended in 2003 when the European Union approved the higher-dose 500 Accuhaler for the symptomatic treatment of severe COPD, i.e., ...
Novartis’ Ultibro Breezhaler is more effective in patients at risk of chronic obstructive pulmonary disease (COPD) flare-ups than GlaxoSmithKline’s rival drug, Seretide, according to new data. The ...
LONDON, July 9 (Reuters) - GlaxoSmithKline Plc has won a licence extension in Europe for Seretide, allowing its top-selling inhaler product to be used in a wider population of patients with the lung ...
GlaxoSmithKline said yesterday its combination asthma drug Seretide had become the first drug to reduce the risk of death in patients with chronic obstructive pulmonary disease (COPD). GlaxoSmithKline ...
Basel, April 30, 2014 - Novartis today announced positive first results from the Phase III head-to-head LANTERN study, which showed the superiority of once-daily ...
This study has demonstrated that doubling the dose of Seretide™ administered via the Diskus™ inhaler over a short period is safe and well tolerated. Whilst this is not a recommended treatment approach ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results